Antibodies News and Research

RSS

A new vaccine that may delay cancer recurrence

A therapeutic cancer vaccine being co-developed by the Ludwig Institute for Cancer Research and the Australian biotech company CSL Limited successfully induced a comprehensive immune response in patients and appeared to delay cancer recurrence

21 Jul 2004

Russian scientists incorporate HIV antigen into a tomato

Russian scientists are currently creating a pleasant and harmless vaccine, and edible one at that. So far, they managed to incorporate the protein gene – HIV antigen in tomatoes. The research is supported by International Science and Technology Center.

19 Jul 2004

Results from clinical trial of TA-NIC, therapeutic vaccine for the treatment of nicotine addiction

Xenova Group has announced initial results from the second clinical trial of TA-NIC, the Company's therapeutic vaccine being developed for the treatment of nicotine addiction.

17 Jul 2004

Effective treatment for soft tissue sarcoma (rhabdomyosarcoma)

Rhabdomyosarcoma is a highly malignant aggressive form of soft tissue cancer in children, the causes of which are currently unknown. Although the fibrous growths can be found all over the body they commonly develop around the head, neck, bladder and testes in young boys.

15 Jul 2004

Expansion of clinical trial of an experimental West Nile virus (WNV) treatment

The National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health, has expanded its clinical trial of an experimental West Nile virus (WNV) treatment to about 60 sites throughout the United States and Canada.

15 Jul 2004

Important milestone for any cancer therapy that will be useful for treating patients

Mayo Clinic researchers have manipulated a human antibody to induce an anti-tumor response in living mice that consistently curbs - and often cures - malignant melanoma, one of the most lethal forms of skin cancer and the most common cancer of young adults.

15 Jul 2004

Latest findings on HIV pathogenesis at AIDS Conference in Bangkok

At the XVth International AIDS Conference in Bangkok, Thailand, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases and chief of the NIAID Laboratory of Immunoregulation (LIR), will present his laboratory’s latest findings on how aberrant immune activation underlies HIV pathogenesis.

15 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

Human antibodies that thwart the SARS virus in mice can be mass-produced quickly

Human antibodies that thwart the SARS virus in mice can be mass-produced quickly using a new laboratory technique developed by an international research team collaborating with the National Institute of Allergy and Infectious Diseases (NIAID).

12 Jul 2004

Anal cancer is on the rise in both sexes

Anal cancer is on the rise in both sexes, particularly among American men, and changing trends in sexual behavior — combined with current tobacco use and infection by a specific strain of the human papillomavirus — may help explain the increase.

9 Jul 2004

A new protocol for bone marrow transplants

A new protocol for bone marrow transplants, which does not require the destruction of the recipient’s immune system before transfer of the new bone marrow, is described by a group of Oxford scientists

5 Jul 2004

Rabies infections in organ donor and transplant recipients

On June 30, 2004, CDC confirmed diagnoses of rabies in three recipients of transplanted organs and in their common donor, who was found subsequently to have serologic evidence of rabies infection.

2 Jul 2004

Findings into the source of the recent SARS outbreak in Beijing and Anhui Province

It has been more than two months since the Ministry of Health of China notified WHO and the world about an outbreak of SARS in Beijing and Anhui Province.

2 Jul 2004

Oxford Therapeutic Antibody Centre receives Manufacturer’s Authorisation

Oxford University's Therapeutic Antibody Centre (TAC) has received a Manufacturer's Authorisation (Investigational Medicinal Products) from the Medicines and Healthcare Products Regulatory Agency (MHRA).

29 Jun 2004

12 sites testing a new vaccine to prevent anthrax

The phase II trial will evaluate the safety and immunogenic response of a new recombinant anthrax vaccine, known as rPA102. The vaccine candidate consists of recombinant Protective Antigen (rPA), a synthetic protein that induces antibodies designed to prevent illness by neutralizing anthrax toxins, and aluminum hydroxide to enhance the immune response.

29 Jun 2004